NEJM Evidence, a journal from NEJM Group, presents innovative Original Research and fresh, bold ideas in Clinical Trial design and clinical decision-making.
A new trial tested clinicians’ performance on fictional case vignettes in which test results were presented with a single threshold, binary test characteristics, or interval likelihood ratio test characteristics across a range of values. Learn more: eviden.cc/4b2Bokm
𝐍𝐨𝐰 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐢𝐧 𝑵𝑬𝑱𝑴 𝑬𝒗𝒊𝒅𝒆𝒏𝒄𝒆!
A new Public Health Alerts report, published in partnership with @CIDRAP: Outcomes among Pregnant Women with Measles and Their Infants in the United States — Preliminary Analysis, 2025–2026 eviden.cc/4zOqTvv
The authors of a new Clinical Trials Workshop examine the role of atrial fibrillation (AF) burden as an outcome for clinical trials of AF interventions. Read the full article: eviden.cc/4zRprIl#AFib#Cardiology
Systemic processes such as infection, malignancy, and autoimmune disease can unify a febrile prodrome with abdominal and pulmonary symptoms, particularly when hyponatremia, thrombocytopenia, kidney injury, and liver-test abnormalities emerge. Learn more: eviden.cc/47B0gOl
𝗥𝗲𝘃𝗶𝗲𝘄 𝗔𝗿𝘁𝗶𝗰𝗹𝗲: 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗻𝗴 𝗠𝗮𝗹𝗮𝗿𝗶𝗮 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗠𝗼𝘃𝗶𝗻𝗴 𝘁𝗼𝘄𝗮𝗿𝗱 𝗠𝗮𝗹𝗮𝗿𝗶𝗮 𝗘𝗹𝗶𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻
Malaria continues to be a major health challenge worldwide, causing an estimated 282 million cases of illness and 610,000 deaths in 2024, predominantly among African children. Despite recent stagnation in the progress of malaria prevention, the landscape is undergoing rapid
transformation. A new review examines current and emerging approaches to preventing malaria infection and supporting malaria elimination, including vector control, transmission-blocking interventions, chemoprevention, monoclonal antibodies, and vaccines. Next-generation insecticide-treated nets, expanded use of seasonal malaria chemoprevention, and the introduction of RTS,S/AS01 and R21/Matrix-M vaccines are already reshaping control strategies. Looking ahead, long-acting injectable chemoprevention, transmission-blocking medicines and vaccines, and improved surveillance-driven deployment may further accelerate progress. As funding becomes constrained and decision making shifts increasingly to countries where malaria is endemic, effective malaria prevention will depend on locally tailored, integrated combinations of interventions supported by strong surveillance, regulatory capacity, and national leadership.
Read more about these approaches in the Review Article “Preventing Malaria Infections and Moving toward Malaria Elimination” by Andre Marie Tchouatieu, MD, Timothy N.C. Wells, ScD, and Jane Achan, MD: nej.md/4sQ0qLg
“Although the tested [long-lasting insecticidal nets] were shown to be beneficial ... malaria incidence among children assigned [chlorfenapyr-pyrethroid] nets ... remained high. Next-generation nets ... cannot carry the burden of malaria control alone.” eviden.cc/4iowmBX
In an extended analysis of the HORIZON Lp(a) trial, pelacarsen was not associated with a reduction in adverse cardiovascular events when evaluated by treatment exposure, baseline lipid levels, or achieved lipoprotein(a) level. Full results: eviden.cc/4eQEutM#AHA26
"[Chlorfenapyr-pyrethroid] and [piperonyl butoxide-pyrethroid long-lasting insecticidal nets] significantly reduced the incidence of malaria in children in areas of intense pyrethroid resistance in Côte d’Ivoire over 1 year." Full trial results: eviden.cc/4smnj8Y
Should atrial fibrillation burden replace 30 seconds of atrial arrhythmia as the primary endpoint of clinical trials in atrial fibrillation? Learn more in a Clinical Trial Workshop in @NEJMEvidence: eviden.cc/4zRprIl#AFib#Cardiology
𝐉𝐮𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝!
Original Article by S.E. Nissen et al.: Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) eviden.cc/4eQEutM#ScientificSessions26 | @AHAScience
A 58-year-old woman initially had fever and muscle aches, followed by abdominal pain and a nonproductive cough days later. She has right-upper-quadrant tenderness and crackles at the right lung base. How would you build the differential diagnosis? eviden.cc/47B0gOl
A new trial conducted in the UK demonstrated that to quit smoking, e-cigarettes were better than behavioral support alone, but the two together were better yet. Read the full trial results: eviden.cc/48hvH0c
This editorial comments on a trial that found the incidence of malaria was significantly reduced among children in Côte d’Ivoire randomly assigned to use piperonyl butoxide-pyrethroid or chlorfenapyr-pyrethroid vs. pyrethroid-only insecticidal nets. 👉 eviden.cc/4iowmBX
Malaria incidence over 1 year was significantly reduced among children residing in clusters of villages in Côte d’Ivoire randomly assigned to use chlorfenapyr-pyrethroid or piperonyl butoxide-pyrethroid versus pyrethroid-only treated insecticidal nets. eviden.cc/4smnj8Y
“E-cigarettes with no further support were more effective than supportive messaging [in helping people achieve abstinence from smoking]. E-cigarettes with multisession telephone-based support were more effective than e-cigarettes alone.” Learn more: eviden.cc/48hvH0c